Shots:
- Biogen & Stoke have partnered to develop & market zorevunersen for Dravet syndrome with Stoke retaining rights in the US, Canada, & Mexico while leading global development & Biogen securing marketing rights in other regions
- As per the deal, Stoke will get $165M upfront, ~$385M in development & commercial milestones, & net sales-based tiered royalties, where external development will be co-funded (30% Biogen, 70% Stoke). Also, Biogen has an option to license certain future follow-on SCN1A-targeting ASOs with separate terms in its licensed regions
- Stoke plans to initiate global P-III (EMPEROR) trial of zorevunersen in Q2’25 with readout expected in H2’27 which will potentially support regulatory filings worldwide
Ref: Biogen | Image: Biogen & Stoke Therapeutics
Related News:- Royalty Pharma Partners with Biogen to Develop Litifilimab
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
